Shashi Tharoor's World of Words is a weekly column dissecting English language
Merck & Co Inc said on Friday its experimental Covid-19 pill reduced the risk of hospitalisation and death by 30 per cent in a study, according to data from all the patients enrolled in a late-stage study.
The company said the data on the drug molnupiravir, developed with Ridgeback Biotherapeutics, had been submitted to the US Food and Drug Administration ahead of a meeting of its expert advisers on Tuesday.
A planned interim analysis of the data last month showed that 7.3 per cent of those given molnupiravir twice a day for five days were hospitalised and none had died by 29 days after the treatment. That compared with a hospitalisation rate of 14.1 per cent for placebo patients.
ALSO READ:
In the updated data, 6.8 per cent of those given molnupiravir were hospitalized and one person died, while the other placebo group had a hospitalization rate of 9.7 per cent.
Shashi Tharoor's World of Words is a weekly column dissecting English language
Between them the two players are set to receive a stake around $150 million from the Tour's newly-formed enterprise
The four-time Grand Slam winner has enjoyed huge success with her powerful baseline game but has struggled on clay
The Tiago has been instrumental in driving Tata Motors’ consistent growth in the hatchback segment
'Women of My Billion' is set to premiere exclusively on Prime Video on May 3
Aditi and Siddharth recently shared the news of their engagement with an adorable picture
Video shows a red 4WD weaving in and out of traffic, causing a collision on the road shoulder
India captain Rohit Sharma said he is not a fan of the rule as it will hold back the development of all-rounders